Evidence map›Paper›PMID 31322571›Full record

ArticleJournal of Alzheimer's disease : JAD2019

Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Methodology for Research and Clinical Brain PET Applications.

Fabio Raman, Sameera Grandhi, Charles F Murchison, Richard E Kennedy, Susan Landau, Erik D Roberson, Jonathan McConathy, Alzheimer’s Disease Neuroimaging Initiative

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Dynamic Amyloid PET: Relationships toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Fabio RamanDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Sameera GrandhiDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Charles F MurchisonAlzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Richard E KennedyAlzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Susan LandauHelen Wills Neuroscience Institute, University of California at Berkeley, Berkeley, CA, USA.
Erik D RobersonAlzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Jonathan McConathyDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Alzheimer’s Disease Neuroimaging Initiative
University of Alabama at Birmingham · USUniversity of California, Berkeley · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008361 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YACOUBIAN, TALENE ALENE · 1992 to 2024
$16.8M
Validation of Online Methods to Predict and Monitor Cognitive DeclineRF1AG059009 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NOSHENY, RACHEL LAUREN · 2018 to 2018
$6.2M
NIA NIH HHS RF1 AG059009NIA NIH HHS U01 AG024904NIGMS NIH HHS T32 GM008361
6 · The paper itself

Abstract

backgroundTools for efficient evaluation of amyloid- and tau-PET images are needed in both clinical and research settings.

objectiveThis study was designed to validate a semi-automated image analysis methodology, called Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER). We tested BLAzER using two different segmentation platforms, FreeSurfer (FS) and Neuroreader (NR), for regional brain PET quantification in participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset.

methods127 amyloid-PET and 55 tau-PET studies with volumetric MRIs were obtained from ADNI. The BLAzER methodology utilizes segmentation of MR images by FS or NR, then visualizes and quantifies regional brain PET data using FDA-cleared software (MIM), enabling quality control to ensure optimal registration and to detect segmentation errors.

resultsBLAzER analysis required ∼5 min plus segmentation time. BLAzER using FS segmentation showed strong agreement with ADNI for global amyloid-PET standardized uptake value ratios (SUVRs) (r = 0.9922, p < 0.001) and regional tau-PET SUVRs across all Braak staging regions (r > 0.97, p < 0.001) with high inter-operator reproducibility (ICC > 0.97) and nearly identical dichotomization as amyloid-positive or -negative (2 discrepant cases out of 127). Comparing FS versus NR segmentation with BLAzER, global SUVRs were strongly correlated for amyloid-PET (r = 0.9841, p < 0.001), but were systematically higher (4% on average) with NR, likely due to more inclusion of white matter with NR-defined regions.

conclusionsBLAzER provides an efficient methodology for regional brain PET quantification. FDA-cleared components and visualization of registration reduce barriers between research and clinical applications.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseBiomarkersBiomedical ResearchBrainFemaleHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission TomographyBiomarkers[18F]AV-1451[18F]AV-45amyloid-βbrain segmentationneuroimagingpositron emission tomographytau

Identifiers

PMID31322571
PMCPMC6745194
OpenAlexW2957601426

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.